证券代码：688261 证券简称：东微半导 公告编号：2025-053 苏州东微半导体股份有限公司 关于变更公司注册资本、修订《公司章程》并办理工 商变更登记及修订内部治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州东微半导体股份有限公司（以下简称"公司"）于2025年12月3日召开 第二届董事会第十八次会议，审议通过了《关于变更注册资本、修订<公司章程> 并办理工商变更登记的议案》及《关于修订<内部审计制度>的议案》，其中《关 于变更注册资本、修订<公司章程>并办理工商变更登记的议案》尚需提交公司股 东会审议。具体情况如下： 一、关于变更公司注册资本的相关情况 （一）变更公司注册资本的情况 公司于2025年7月15日召开第二届董事会第十二次会议以及第二届监事会第 十二次会议，分别审议通过了《关于<公司2025年限制性股票激励计划（草案）> 及其摘要的议案》及《关于<公司2025年限制性股票激励计划实施考核管理办法> 的议案》，并于2025年8月1日经公司2025年第一次临时股东会审议通过。后续公 司分 ...

证券代码：688261 证券简称：东微半导 公告编号：2025-052 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第二次临时股东会 召开日期时间：2025 年 12 月 19 日 13 点 30 分 苏州东微半导体股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 召开地点：江苏省苏州市工业园区金鸡湖大道 99 号纳米城东南区 65 栋苏州 东微半导体股份有限公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 19 日 至2025 年 12 月 19 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东会召开日期：2025年12月19日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现 ...

东微半导公告称，公司于2025年12月3日召开相关会议，审议通过2026年度日常关联交易预计议案。 2026年1-7月预计与关联方客户A出售商品及服务金额1.55亿元，占同类业务比例15.45%；2025年1-10月 实际发生9845.86万元，占比9.81%。公司与客户A关联关系将于2026年7月底解除。该事项尚需股东会 审议，关联股东需回避表决。保荐机构中金公司同意上述预计事项。 ...

Core Insights - Shanghai Dongnaozhihe Technology Co., Ltd. has been officially registered and established in the Minhang "Brain Intelligence Land," marking a significant step in gathering global cutting-edge brain-computer interface (BCI) technology resources [1][3] Company Overview - Dongnaozhihe has attracted top talents from the semiconductor and neuroscience fields, with founder Gong Yi having extensive experience in semiconductor technology and industrialization [3] - The company has partnered with an experienced international team specializing in biosensor chip development to work on ultra-low power, high-throughput brain-specific chips and systems [3] - The core team is led by Pei Weihua, a researcher from the Chinese Academy of Sciences, who has over 20 years of experience in neural interface technology [3] Technology and Innovation - Dongnaozhihe aims to develop a unique hydraulic-driven flexible neural touch electrode technology, focusing on both research-grade and medical-grade applications [3] - The company plans to establish a comprehensive core technology layout for invasive brain-computer interfaces, aspiring to become one of the top global BCI companies [3] Industry Environment - Since the 12th Five-Year Plan, brain science and artificial intelligence research, including BCI, have gained increasing importance in China's national science and technology planning [3] - Recent policies at both national and local levels have been introduced to encourage the development of BCIs, including integrating relevant technologies into medical insurance systems and establishing dedicated wards in medical institutions [3] Strategic Goals - Dongnaozhihe intends to leverage Shanghai's advantages in talent, capital, and industrial chain support to accelerate technology transfer and product development [4] - The company will actively participate in the formulation of domestic and international standards and the construction of the industry ecosystem [4] - The National Brain-Computer Interface Conference is scheduled to be held in December 2025 at Brain Intelligence Land, bringing together global experts and technology teams to discuss the future applications and development paths of the BCI industry in China [4]

Group 1 - Shanghai Dongnao Zhihuo Technology Co., Ltd. has officially registered and established the Shanghai Brain-Computer Interface Future Industry Cluster, the first of its kind in the country, focusing on brain-computer interface technology development [2] - The company has gathered top talents from the semiconductor and neuroscience fields, with founder Gong Yi also serving as the chairman of Dongwei Semiconductor (stock code: 688261.SH) [2] - Dongnao Zhihuo aims to become a leading global brain-computer interface company by developing proprietary hydraulic-driven flexible neural interface electrode technology [2] Group 2 - Since the 12th Five-Year Plan, brain science and artificial intelligence research, including brain-computer interface technology, have gained increasing importance in China's national science and technology planning [3] - The government is supporting the industry through top-level design, with initiatives to promote the integration of brain-computer interfaces into medical insurance and the establishment of specialized wards [3] - The 2025 National Brain-Computer Interface Conference will be held in December at the Brain-Intelligence Heaven cluster, bringing together global experts and cutting-edge technology talents [3]

Core Viewpoint - The company focuses its business primarily on the domestic market, with a low proportion of overseas sales [2] Summary by Relevant Sections - **Business Focus** - The company's operations are concentrated in the domestic market, indicating a strategic choice to prioritize local opportunities over international expansion [2]

证券代码：688261 证券简称：东微半导 公告编号：2025-050 苏州东微半导体股份有限公司 关于举办 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 会议问题征集：投资者可于 2025 年 11 月 21 日（星期五）14:00 点前访 问网址 https://eseb.cn/1t8J593VBe0 或使用微信扫描下方小程序码进行会前 提问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的 问题进行回答。 一、说明会类型 苏州东微半导体股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日在上海证券交易所网站（www.sse.com.cn）披露了《苏州东微半导体股份有限 公司 2025 年第三季度报告》。为便于广大投资者更加全面深入地了解公司经营业 绩、发展战略等情况，公司定于 2025 年 11 月 21 日（星期五）15:00-16:00 在 "价值在线"（www.ir-online.cn）举办 2025 年第三季度业绩说 ...

Group 1 - Dongwei Semiconductor (688261.SH) closed at 66.91 yuan, with a decline of 2.25% [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 10, 2022, issuing 16.844092 million shares, accounting for 25.00% of the total shares post-issuance, at a price of 130.00 yuan per share [1] - Currently, the stock is in a state of decline from its initial offering price [1] Group 2 - The total funds raised by Dongwei Semiconductor during its IPO amounted to 2.19 billion yuan, with a net amount of 2.007 billion yuan after deducting issuance costs, which was 1.068 billion yuan more than the original plan of 939 million yuan [1] - The funds are intended for upgrading and industrialization of super junction and shielding gate power devices, R&D of new structure power devices, and construction of a research and development engineering center [1] - The total issuance costs were 183 million yuan, with the lead underwriter, China International Capital Corporation, receiving 156 million yuan in underwriting fees [1] Group 3 - The company announced a cash dividend of 1.476 yuan per share (including tax) and a capital reserve transfer of 0.4 shares for every share held, resulting in a total cash dividend distribution of approximately 99.45 million yuan and a transfer of 26.95 million shares [2] - Following this distribution, the total share capital will increase to 94,326,914 shares [2] - For the 2023 annual dividend distribution, the company plans to distribute 1.79 yuan in cash for every 10 shares and transfer 3 shares for every 10 shares held, with the record date set for July 3, 2024 [2]

Core Viewpoint - The Chinese innovative drug market is entering a rapid development phase, with local leading companies like Heng Rui benefiting from policy support and industry expansion opportunities [1] Company Performance - Heng Rui Pharmaceutical reported a revenue of 23.188 billion yuan for the first three quarters of 2025, a year-on-year increase of 14.85%, and a net profit of 5.751 billion yuan, up 24.50% [2] - The company has received a total cash dividend of over 9.3 billion yuan, enhancing investor returns [1] - The company has established a differentiated competitive advantage through over 50 billion yuan in R&D investment and has 24 innovative drugs approved for sale in China [1] Industry Trends - The innovative drug sector is experiencing accelerated commercialization and increased business development (BD) transactions, leading to a sustained trend of rapid growth in performance [1] - Other innovative drug companies, such as Zai Lab and DiZhe Pharmaceutical, are also reporting significant revenue growth, with Zai Lab achieving a 54.49% increase in revenue to 593 million yuan [3] - The industry is expected to continue its growth trajectory, supported by favorable national policies and increasing international collaboration [4][5] R&D Focus - Heng Rui's innovative drugs, including Rivoceranib and Darsylis, are addressing unmet clinical needs, contributing to their revenue growth [2] - Zai Lab emphasizes its differentiated product pipeline focusing on oncology and autoimmune diseases, aiming to fill domestic gaps in treatment options [3] - The industry is witnessing a rise in R&D investments, with companies like Yi Fang Bio reporting a total R&D investment of 190 million yuan for the first three quarters of 2025 [4] Future Outlook - Analysts predict a new round of growth for the pharmaceutical sector, particularly in innovative drugs, as the international standing of Chinese innovative drug companies rises [5] - The innovative drug sector is expected to remain a key investment theme in the pharmaceutical industry through 2026, driven by increased BD transactions and international collaborations [5]

Summary of Conference Call Company Overview - **Company**: Dongwei Peninsula - **Industry**: Power Semiconductor Design Key Financial Highlights - **Revenue**: - For the first nine months, revenue reached 963 million yuan, a year-on-year increase of 41.6% [2][3] - Third-quarter revenue was 348 million yuan, a year-on-year growth of 3% [2] - **Net Profit**: - Net profit attributable to shareholders for the first nine months was 48.55 million yuan, up 58.46% year-on-year [2] - Third-quarter net profit was approximately 20.9 million yuan, a year-on-year increase of 53.09% [2] - **Non-recurring Profit**: - Non-recurring net profit for the first nine months was 20.38 million yuan, a significant increase of 374.48% [2] - Non-recurring net profit for the third quarter was 16.44 million yuan, up 524.69% year-on-year [3] Product and Market Insights - **Product Segmentation**: - Core products include Superjet, accounting for over 70% of revenue, and medium-low voltage shielding products, which exceeded 20% [6][7] - AI-related products are categorized under industrial and communication power supplies, contributing significantly to revenue [8] - **Growth Areas**: - The company has seen substantial growth in new power device modules, with revenue reaching over 10 million yuan [7] - AI-related revenue is expected to grow, with a stable upward trend in demand across various sectors [8] Supply Chain and Cost Management - **Supply Chain Strategy**: - The company is actively stocking up on wafer resources, particularly 12-inch wafers, to meet future demand [19][20] - Inventory levels have increased, reflecting a strategic decision to prepare for anticipated demand, especially in AI [18][19] - **Gross Margin**: - Average gross margin for the third quarter was around 16%, showing a slight year-on-year increase of 1.01 percentage points [11] Future Outlook - **Quarterly Projections**: - The company expects to maintain a stable revenue distribution, with the fourth quarter traditionally accounting for a higher percentage of annual revenue [16][17] - **Product Development**: - Focus on GaN (Gallium Nitride) technology is a priority, with ongoing partnerships and product development expected to yield results in the coming year [22][23] - **Market Positioning**: - The company aims to leverage its strengths in low-voltage products and expand into new markets, particularly in the context of increasing electrification and battery usage [30][31] Additional Insights - **Strategic Partnerships**: - Collaborations with leading semiconductor manufacturers and suppliers are being established to enhance product offerings and market competitiveness [22][26] - **Investment in R&D**: - The company is committed to investing in advanced technologies and projects to ensure long-term growth and innovation [31] This summary encapsulates the key points discussed during the conference call, highlighting the company's financial performance, product insights, supply chain strategies, and future outlook.